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Abstract : Angiotensin I (AII) plays an important role in various cardiovascular diseases 
associated with vascular smooth muscle cel (VSMC) growth and migration. In our previous 
study， we investigated the effect of olmesartan， an angiotensin I receptor blocker， on AII 
induced Src tyrosine kinase， extracellular signal-regulated kinases 1/2 (ERK1I2) and c-J un 
N目terminalkinase (JNK) activation and rat aortic smooth muscle cel (RASMC) migration. 
We found that olmesartan inhibit巴dAII-induced ERK1/2 and JNK activation at lower 
concentrations. On the other hand， PP2， a Src tyrosine kinase inhibitor， also inhibited AII司
induced ERK1I2 and JNK activation， but its effect on ERK1I2 was less pronounced than 
that of olmesartan. How巴ver，both olmesartan and PP2 potently inhibited AII-induced 
RASMC migration. In the present study， we investigated the involvement of Src on AII-
induced migration of RASMC using Src siRNA for gene silencing. Src siRNA was successful1y 
introduced into RASMC using transfection proc巴dures.We found that the inhibitory effect 
of Src siRNA on AII-induced JNK activation was more potent than on ERKl/2 activation in 
RASMC. 1n addition， Src siRNA effectively inhibited AII-induced RASMC migration to an 
extent similar to PP2. From these findings， itwas inferred that direct inhibition of Src may be 
an巴ffectiveoption for VSMC growth and migration. Pharmacological or genetic inhibition of Src 
may be a strategy that can be used in addition to renin】angiotensinblockade for cardiovascular 
diseases involving AII， such as hypertension and atherosclerosis. 
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Fig， 1.Comparison of出einhibitory effects of olmesartan (Olm) and PP2 on angiotensin I (AI)“induced extracellular signal-
regulated kinases (ERK1I2) and c-Jun N-terminal kinase (JNK) activations in rat aortic smooth muscle cels (RASMCs)， 
After culturing in serum-free medium for 48 h， the cels were not pretreated， or pretreated with 10 nM olmesartan 
for 5 min or 10μM PP2 for 1 h， Then， the cells were stimulated with 10 nM of AII or left unstimulated for 5 min 
The activities of ERK1!2 (A) and JNK (B) were measured as described under Materials and Methods， Densitometric 
analysis of each value was normalized by arbitrarily setting the densitometric value of control cels (Cont.) to 1.0， The 
asterisks represent values that were significantly different from the values of Ang I stim叫ationin normal RASMC (帥p
< 0，01)， Each va1ue represents a mean土 S，D，(n = 3)， (Modified from Ref， 19) 
(27) 
ルメサルタン (RNH-6270) が，培養ラット大動脈平








(Fig. 1及び 3).そこで本研究では， AII刺激による
RASMC細胞内情報伝達系と細胞遊走における Srcチ
ロシンキナーゼの役割について明らかにする目的で，





ほか以下の試薬を購入した:A I (Peptide Institute， 
アンジオテンシン E刺激による血管平滑筋細胞の遊走に対する Src阻害と MAPキナ}ゼ阻害効果の比較
実験材料及び方法
薬試
extracellular signal同regulatedkinase 1/2 (ERK1/2) 9)， 































































Fig. 2. Inhibitory effect of olmesartan on angiotensin I (AI) -induced rat aortic smooth muscle cel (RASMC) migration. Cells 
were not pretreated or were pretreated with olmesartan (Olm) for 5 min. Then， tbe cels were stimulated with 100 nM 
of AII， or left unstimulated， wounded using a yellow pipette tip， and cultured for 24 h. After these cels were stained and 
photographed， the cels between the 2 rims were counted under 5 different microscope fields. Values were normalized 
by arbitrarily setting the counts of control cels to l.0. The asterisks represent values that were significantly different 
from the values of AII stimulation in normal RASMC (， P < 0.05ゾ申P く 0.01).Each value represents a mean士 S.D.(n 





Inc.，Osaka) ; PP2 (Calbioch巴m，San Diego， CA， 
USA) ; phospho【ERK1/2抗体と phospho-JNK抗体
(Cell Signaling Technology， Danver， MA， USA) ; Src 
抗体 (UpstateTechnology， Lake Placid， NY， USA) 
Srcの non-silencingsiRNA (B】BridgeInternational， 
Inc.， Cupertino， CA， USA) ; Src の Stealthselect 






動物の処理はUSN ational Institutes of Health (NIH 
publication No. 85-23， revised 1985)から出版された




(100 U/ml) とstreptomycin(100μ g/ml) を含む
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大動脈を約 3mm四方片に切り， 3つの 35mm培養
皿 (Falcon，Becton Dickinson， CA， USA) に内膜面
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Fig. 3. Inhibitory efect of olmesartan (Olm) and PP2 on angiotensin I (AI) -induced rat aortic smooth muscle cel (RASMC) 
migration. Cells were not pretreated. or were pretreated with 100μM olmesartan for 5 min or 1 μM  PP2 for 1 
h. Then， the cels were stimulated with 100 nM of AII or left unstimulated， wounded using. a yellow pipette tip， and 
cultured for 24 h. After the cels were stained and photographed， the cels between the 2 rims were counted under 5 
different microscope丑elds.Values were normalized by arbitrarily setting the counts of control cels (Cont.) to 1.0. The 
asterisks represent values that were significantly different from the values of AII stimulation in normal RASMC (" Pく
0.01). Each value represents a mean士 S.D.(1ニ 3).(Modified from Ref. 19) 











としない Src の non-silencingsiRNAを negative






20 mM  Tri治s-HCα1(pH 7.4)， 150 mM  N aCI， 1 mM  
ethylenediaminetetraacetic acid (EDT A)， 1 mM  
ethyleneglycot巴traaceticacid (EGT A)， 1 % Triton 
X】100，2.5 mM sodium pyrophosphate， 1 mM s 
-glycerophosphate， 1 mM sodium orthovanadate， 1 
μg/mlleupeptin並びに 1mM phenylmethylsulfonyl 
fiuorideを含む細胞溶解液を細胞に添加し 4'Cにて
30-60分間作用させた.その後，凍結融解に続いて
超音波処理を行った後に遠心分離 (16，000x g，40C) 
し上清の蛋白濃度を proteinassay bicinchoninate 
kit (Nacalai Tesque， Kyoto) を用いて測定した.細
胞可溶化液を sodiumdodecyl sulfate (SDS) ポリ
アクリルアミドゲル電気泳動し，その蛋白を既報の
方法 21 に基づいて polyvinylidenefiuoride (PVDF) 
membran巴s(Bio-Rad， CA USA) に転移させた.そ
の PVDFmembraneを5%スキムミルク含有 0.1% 
Tris-buffered saline Tween】20(TBS戸T) でブロッキ
ングし， 1次抗体， 2次抗体 (horseradishperoxidase 
conjugated) と順 に 反 応させた対象を enhanced
chemiluminescence (Amersham， Buckinnghamshire， 
UK) を用いて発光させてフィルムに感光し， NIH 
imageによる濃度測定により定量化した
Wound healing assay 











実験は 3回行い，測定値を means土 S.D.(標準偏差)
で示した 2-W ay analysis of varianc巴(ANOVA)で
集団の偏差に差がないことを決定し，各群の有意差は
Fisher' s post【hoctestを伴う modifiedιtestで判定し
た p< 0.05を統計的に有意であると判定した
結 果













次に RASMCの AIIによる ERKl/々2，]NK及びSrc
活性化の濃度依存性を検討した RASMCにおける
ERKl/2及び]NKはAIIの濃度依存的に活性化され，
AII 濃度が 100nMで最大となった.一方， SrcはA
Eの濃度依存的に活性化され， A I 濃度が 10nMで
ピークを迎えた.これらの結果は，以前に報告した我々









検討するため， Src silencingのための SrcsiRNA 
の至適化を行った (Fig.4) 各 SrcsiRNA量での
Src knockdownの程度は，抗 Src抗体によるウエ
スタンプロットによって行い， scramble siRNA (25 
pmol， B-Bridge) を negativecontrolとした. Src 
knockdownの効率は， Src siRNA量を増加させるほ
ど上昇し， 25pmolでほぼピークの 80%に達した (Fig

























効果を比較検討した 19) その結果，オルメサルタン (10




(Fig. 1) この ERK1/2とJNKの活性化に対する
Srcの関与の程度を明らかにするため， Src siRNAに
よる発現阻害を行った細胞を用いて同様の実験を行っ
た (Fig. 5). その結果， PP2を用いた実験結果と同
機耕輔費襲輔炉問耕輔剛山輔験嚇輔蝉糊脚
む 闘む 2.5 12.5 25 50 75 
畠rcsiR陪A(pmol.4盛時
Fig. 4. Effect of siRNA for Src on Src expression in cultured rat aortic smooth muscle cels (RASMCs). Cells were transfected 
with the indicated amount of Src siRNA or negative control (NC) siRNA for 48h. After culturing in serum-free medium 
for 24 h， cels were harvested and assayed. Src expression was measured as described under Materials and Methods. 
Densitometric analysis of each value was normalized by arbitrarily setting the densitometric value of control cels to 1.0. 
Each value represents a mean土 SD(n = 3). The asterisks represent values that were significantly different from the 
values of the control in normal RASMC (" P < 0.01) 
アンジオテンシン E刺激による血管平滑筋細胞の遊走に対する Src阻害と MAPキナーゼ阻害効果の比較 (31) 
様に SrcsiRNAのERK1/2活性化に対する阻害効果
は中程度であり， ]NK活性化も完全には抑制されな
























害薬である PP2のそれと比較検討した 19) オルメサ
ルタンは Allによる RASMC遊走の阻害に高濃度を
要したものの (Fig. 2)， PP2は比較的低い濃度で A
E刺激による RASMC遊走を強力に阻害した (Fig
3) .これらの結果と， PP2の顕著ではない MAPキ










Fig.5. Effect of Src siRNA on angiotensin I (AI) -induced extracellular signal-regulated kinases (ERK1I2) and c.Jun 
N.terminal kinase (JNK) acti、rationsin rat aortic smooth muscle cels (RASMCs). Cel1s were transfected with 25 pmol 
of Src siRNA or the same amount of negative control siRNA for 48h. After culturing in serum.free medium for 24h， 
transfected cels were treated with AII， or left untreated， for 5 min. ERK1/2 (A) and JNK (B) activities were measured 
as described under νlaterials and Methods. Densitometric analysis of each v日luewas normalized by arbitrarily setting 
the densitometric value of control cels to 1.0. Each value represents a mean土 SD(nニ 3).The asterisks represent 









































て， Src阻害薬の PP2が ERKl/2活性化を中程度に
抑制し， JNK活性化の阻害は ERKl/2の阻害より強
力で， PP2の阻害効果に差がみられた 19) 本研究で我々
は， PP2の代わりに SrcsiRNAを用いて同様の検討
を行い，やはり Src阻害は， AII刺激による ERKl/2
活性化よりも JNKの活性化を顕著に阻害することが
確認された (Fig，5) この実験結果は， Srcが少なく
とも部分的に AII刺激による ERKl/2とJNKの活
性化の上流に存在することを示している.また， Src 
siRNAによる Src阻害は， AII刺激による ERKl/2
活性化よりも JNKの活性化を顕著に抑制したことか
ら， AII刺激による Srcのリン酸化は ERKl/2の活
思 10 
Sr時剖日制A
Fig. 6. Inhibitory effect of Src siRNA on angiotensin I (AI) -induced rat aortic smooth muscle cel (RASMC) migration. Cells 
were transfected with 25 pmol of Src siRNA or the same amount of negative control siRNA for 48 h. After culturing in 
serum目freemedium for 24 h， transfected cels were stimulated with 100 nM of AII or left unstimulated. Then. the cels 
were wounded using a yellow pipette tip， and cultured for 24 h. After the cels were stained and photographed， the cels 
between the 2 rims were counted under 5 di宜erentmicroscope fields. Values were normalized by arbitrarily setting 
the counts of control cels to 1.0. The asterisks represent values that were significantly different from the values of AII 
stimulation in normal RASMC作P< 0.01). Each value represents a mean士 S.D.(nニ 3)
























(Fig. 1及び3) そこで我々は， PP2の代わりに Src
siRNAを用いて AII刺激による RASMC遊走の阻害
効果を検討した.以前の我々の検討 (Fig.3) と同様
に， Src siRNAは AII刺激による RASMC遊走を強
力に阻害した (Fig.6) これらの実験結果は， Srcは
細胞の遊走において決定的な因子であるという以前の
研究報告の結果と一致している 7，8) Src siRN AはA
E刺激による ERKll2の活性化に対しては部分的な
阻害効果を示したが (Fig. 5)， Src siRNAはAII刺
激による RASMCの遊走に対しては強力な阻害効果






で阻害したという結果は， A I刺激による ERK1/2，
]NKの活性化に対する阻害の結果と一致しない (Fig.
1，及び2) しかしながら，実験で用いた Wound















明らかにした.さらに， Src siRNAを用いた RASMC
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